Stocks
Heron Therapeutics (HRTX) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -137.9% | -251.1% | -249.3% | -164.1% | -81.7% | -15.1% | ||
| Changes by years, y/y, % | +100pp | -113pp | +2pp | +85pp | +82pp | -19.2% | |||
Heron Therapeutics. EBITDA margin, %
Heron Therapeutics. EBITDA margin, changes, pp
Heron Therapeutics (HRTX) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | -75.5% | -22.9% | -11.9% | -16.1% | -10.5% | -15.1% | |
| Changes by years, y/y, % | +80pp | +45pp | +97pp | +115pp | +65pp | |||
| Changes by quarters, q/q, % | +56pp | +53pp | +11pp | -4pp | +6pp | |||
